Hepatocyte Growth Factor - Drugs In Development, 2021
Hepatocyte Growth Factor - Drugs In Development, 2021
SUMMARY
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Hepatocyte growth factor (HGF) is a paracrine cellular growth and morphogenic factor secreted by mesenchymal cells and stimulates epithelial cell proliferation, motility, morphogenesis and angiogenesis in various organs via tyrosine phosphorylation of its receptor. It has a major role in embryonic organ development, specifically in myogenesis, in adult organ regeneration and in wound healing. In addition, HGF exerts protective effects on epithelial and non-epithelial organs (including the heart and brain) via anti-apoptotic and anti-inflammatory signals.
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) pipeline Target constitutes close to 18 molecules. The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 5, 4, 5 and 4 respectively. Report covers products from therapy areas Oncology, Central Nervous System, Cardiovascular, Gastrointestinal, Dermatology, Genetic Disorders, Genito Urinary System And Sex Hormones, Hematological Disorders, Metabolic Disorders and Respiratory which include indications Amyotrophic Lateral Sclerosis, Critical Limb Ischemia, Glioblastoma Multiforme (GBM), Melanoma, Ovarian Cancer, Peripheral Arterial Disease (PAD)/Peripheral Vascular Disease (PVD), Acute Renal Failure (ARF) (Acute Kidney Injury), Acute Spinal Cord Injury, Alzheimer's Disease, Anxiety Disorders, Arteriosclerosis, Breast Cancer, Charcot-Marie-Tooth Disease Type I A, Colon Cancer, Colorectal Cancer, Coronary Artery Disease (CAD) (Ischemic Heart Disease), Dementia, Depression, Diabetic Ischemic Foot Ulcers, Diabetic Neuropathic Pain, Gallbladder Cancer, Gastric Cancer, Hepatocellular Carcinoma, Intermittent Claudication, Leiomyosarcoma, Liver Fibrosis, Lung Cancer, Lung Injury, Lymphedema, Lymphoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Cancer, Myocardial Infarction, Nasopharyngeal Cancer, Neuromuscular Disorders, Non-Small Cell Lung Cancer, Occlusive Arterial Disease (OAD), Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Parkinson's Disease, Peripheral Artery Occlusive Disease (PAOD), Post-Operative Pain, Prostate Cancer, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Scar, Solid Tumor, Thromboangiitis obliterans (Buerger disease) and Ulcers.
The latest report Hepatocyte Growth Factor - Drugs In Development, 2021, outlays comprehensive information on the Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Hepatocyte growth factor (HGF) is a paracrine cellular growth and morphogenic factor secreted by mesenchymal cells and stimulates epithelial cell proliferation, motility, morphogenesis and angiogenesis in various organs via tyrosine phosphorylation of its receptor. It has a major role in embryonic organ development, specifically in myogenesis, in adult organ regeneration and in wound healing. In addition, HGF exerts protective effects on epithelial and non-epithelial organs (including the heart and brain) via anti-apoptotic and anti-inflammatory signals.
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) pipeline Target constitutes close to 18 molecules. The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 5, 4, 5 and 4 respectively. Report covers products from therapy areas Oncology, Central Nervous System, Cardiovascular, Gastrointestinal, Dermatology, Genetic Disorders, Genito Urinary System And Sex Hormones, Hematological Disorders, Metabolic Disorders and Respiratory which include indications Amyotrophic Lateral Sclerosis, Critical Limb Ischemia, Glioblastoma Multiforme (GBM), Melanoma, Ovarian Cancer, Peripheral Arterial Disease (PAD)/Peripheral Vascular Disease (PVD), Acute Renal Failure (ARF) (Acute Kidney Injury), Acute Spinal Cord Injury, Alzheimer's Disease, Anxiety Disorders, Arteriosclerosis, Breast Cancer, Charcot-Marie-Tooth Disease Type I A, Colon Cancer, Colorectal Cancer, Coronary Artery Disease (CAD) (Ischemic Heart Disease), Dementia, Depression, Diabetic Ischemic Foot Ulcers, Diabetic Neuropathic Pain, Gallbladder Cancer, Gastric Cancer, Hepatocellular Carcinoma, Intermittent Claudication, Leiomyosarcoma, Liver Fibrosis, Lung Cancer, Lung Injury, Lymphedema, Lymphoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Cancer, Myocardial Infarction, Nasopharyngeal Cancer, Neuromuscular Disorders, Non-Small Cell Lung Cancer, Occlusive Arterial Disease (OAD), Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Parkinson's Disease, Peripheral Artery Occlusive Disease (PAOD), Post-Operative Pain, Prostate Cancer, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Scar, Solid Tumor, Thromboangiitis obliterans (Buerger disease) and Ulcers.
The latest report Hepatocyte Growth Factor - Drugs In Development, 2021, outlays comprehensive information on the Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF)
- The report reviews Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics and enlists all their major and minor projects
- The report assesses Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Overview
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Companies Involved in Therapeutics Development
AnGes Inc
Athira Pharma Inc
AVEO Pharmaceuticals Inc
Beijing SH biotechnology Co Ltd
Helixmith Co Ltd
i2 Pharmaceuticals Inc
Kringle Pharma Inc
Minerva Biotechnologies Corp
Molecular Partners AG
PlateletBio
Yichang Humanwell Pharmaceutical Co Ltd
Yooyoung Pharm Co Ltd
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Drug Profiles
Ad-HGF - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATH-1017 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATH-1020 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
beperminogene perplasmid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
donaperminogene seltoplasmid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ficlatuzumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate HGF for Critical Limb Ischemia and Chronic Post-Operative Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate HGF for Liver Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to activate HGF for Lung Injury - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate HGF for Neuro Muscular Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to activate HGF for Peripheral Artery Occlusive Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KP-100IT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit Hepatocyte Growth Factor for Metastatic Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MP-0250 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NK-4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SL-186 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SL-188 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YYB-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Dormant Products
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Discontinued Products
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Product Development Milestones
Featured News & Press Releases
Jul 06, 2021: Athira Pharma announces initiation of open label extension study for LIFT-AD and ACT-AD clinical trials of ATH-1017 for Alzheimer’s disease
Jun 07, 2021: AVEO Oncology to host key opinion leader webinar on ficlatuzumab in head and neck squamous cell carcinoma
May 21, 2021: XOMA licensee AVEO to present significant clinical data on ficlatuzumab at 2021 ASCO Annual Meeting
May 19, 2021: AVEO Oncology announces positive results from randomized phase 2 study of ficlatuzumab in combination with cetuximab in pan-refractory, metastatic HNSCC
Apr 23, 2021: Helixmith announces poster presentations at the 2021 American Academy of Pain Medicine Meeting
Mar 10, 2021: Helixmith announces first patient enrolled in phase 2 study of Engensis (VM202) for Amyotrophic Lateral Sclerosis
Jan 22, 2021: Helixmith: Results from phase 3 gene therapy trial for diabetic peripheral neuropathy published online by Clinical and Translational Science
Dec 08, 2020: Athira Pharma awarded $15 million grant from National Institute on Aging to support ACT-AD clinical trial in Alzheimer’s Disease
Dec 01, 2020: Athira Pharma announces initiation of patient dosing for ACT-AD clinical trial of ATH-1017, small molecule HGF/MET activator, for treatment of mild-to-moderate Alzheimer’s disease
Nov 18, 2020: Helixmith announces first patient enrolled in phase 3 study of Engensis (VM202) for diabetic peripheral neuropathy
Oct 21, 2020: Athira Pharma to host educational webinar on the predictive nature of P300 to determine clinical benefit of Alzheimer’s Disease treatments
Oct 01, 2020: Athira Pharma announces initiation of patient dosing for the LIFT-AD study, a Phase 2/3 clinical trial to evaluate ATH-1017 for treatment of mild-to-moderate Alzheimer's Disease
Jul 27, 2020: Helixmith: VM202 CMT Phase I/IIA Trial Launched
Mar 27, 2020: AVEO Oncology and Biodesix to discontinue CyFi-2 study of Ficlatuzumab in Relapsed and Refractory AML in response to public health crisis
Feb 18, 2020: Helixmith provides update of gene therapy Phase 3 Trial for Painful Diabetic Peripheral Neuropathy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Overview
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Companies Involved in Therapeutics Development
AnGes Inc
Athira Pharma Inc
AVEO Pharmaceuticals Inc
Beijing SH biotechnology Co Ltd
Helixmith Co Ltd
i2 Pharmaceuticals Inc
Kringle Pharma Inc
Minerva Biotechnologies Corp
Molecular Partners AG
PlateletBio
Yichang Humanwell Pharmaceutical Co Ltd
Yooyoung Pharm Co Ltd
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Drug Profiles
Ad-HGF - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATH-1017 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATH-1020 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
beperminogene perplasmid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
donaperminogene seltoplasmid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ficlatuzumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate HGF for Critical Limb Ischemia and Chronic Post-Operative Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate HGF for Liver Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to activate HGF for Lung Injury - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate HGF for Neuro Muscular Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to activate HGF for Peripheral Artery Occlusive Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KP-100IT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit Hepatocyte Growth Factor for Metastatic Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MP-0250 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NK-4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SL-186 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SL-188 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YYB-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Dormant Products
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Discontinued Products
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Product Development Milestones
Featured News & Press Releases
Jul 06, 2021: Athira Pharma announces initiation of open label extension study for LIFT-AD and ACT-AD clinical trials of ATH-1017 for Alzheimer’s disease
Jun 07, 2021: AVEO Oncology to host key opinion leader webinar on ficlatuzumab in head and neck squamous cell carcinoma
May 21, 2021: XOMA licensee AVEO to present significant clinical data on ficlatuzumab at 2021 ASCO Annual Meeting
May 19, 2021: AVEO Oncology announces positive results from randomized phase 2 study of ficlatuzumab in combination with cetuximab in pan-refractory, metastatic HNSCC
Apr 23, 2021: Helixmith announces poster presentations at the 2021 American Academy of Pain Medicine Meeting
Mar 10, 2021: Helixmith announces first patient enrolled in phase 2 study of Engensis (VM202) for Amyotrophic Lateral Sclerosis
Jan 22, 2021: Helixmith: Results from phase 3 gene therapy trial for diabetic peripheral neuropathy published online by Clinical and Translational Science
Dec 08, 2020: Athira Pharma awarded $15 million grant from National Institute on Aging to support ACT-AD clinical trial in Alzheimer’s Disease
Dec 01, 2020: Athira Pharma announces initiation of patient dosing for ACT-AD clinical trial of ATH-1017, small molecule HGF/MET activator, for treatment of mild-to-moderate Alzheimer’s disease
Nov 18, 2020: Helixmith announces first patient enrolled in phase 3 study of Engensis (VM202) for diabetic peripheral neuropathy
Oct 21, 2020: Athira Pharma to host educational webinar on the predictive nature of P300 to determine clinical benefit of Alzheimer’s Disease treatments
Oct 01, 2020: Athira Pharma announces initiation of patient dosing for the LIFT-AD study, a Phase 2/3 clinical trial to evaluate ATH-1017 for treatment of mild-to-moderate Alzheimer's Disease
Jul 27, 2020: Helixmith: VM202 CMT Phase I/IIA Trial Launched
Mar 27, 2020: AVEO Oncology and Biodesix to discontinue CyFi-2 study of Ficlatuzumab in Relapsed and Refractory AML in response to public health crisis
Feb 18, 2020: Helixmith provides update of gene therapy Phase 3 Trial for Painful Diabetic Peripheral Neuropathy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indications, 2021
Number of Products under Development by Indications, 2021 (Contd..1)
Number of Products under Development by Indications, 2021 (Contd..2)
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021 (Contd..2)
Products under Development by Companies, 2021 (Contd..3)
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by AnGes Inc, 2021
Pipeline by Athira Pharma Inc, 2021
Pipeline by AVEO Pharmaceuticals Inc, 2021
Pipeline by Beijing SH biotechnology Co Ltd, 2021
Pipeline by Helixmith Co Ltd, 2021
Pipeline by i2 Pharmaceuticals Inc, 2021
Pipeline by Kringle Pharma Inc, 2021
Pipeline by Minerva Biotechnologies Corp, 2021
Pipeline by Molecular Partners AG, 2021
Pipeline by PlateletBio, 2021
Pipeline by Yichang Humanwell Pharmaceutical Co Ltd, 2021
Pipeline by Yooyoung Pharm Co Ltd, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Dormant Products, 2021 (Contd..2)
Dormant Products, 2021 (Contd..3)
Discontinued Products, 2021
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indications, 2021
Number of Products under Development by Indications, 2021 (Contd..1)
Number of Products under Development by Indications, 2021 (Contd..2)
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021 (Contd..2)
Products under Development by Companies, 2021 (Contd..3)
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by AnGes Inc, 2021
Pipeline by Athira Pharma Inc, 2021
Pipeline by AVEO Pharmaceuticals Inc, 2021
Pipeline by Beijing SH biotechnology Co Ltd, 2021
Pipeline by Helixmith Co Ltd, 2021
Pipeline by i2 Pharmaceuticals Inc, 2021
Pipeline by Kringle Pharma Inc, 2021
Pipeline by Minerva Biotechnologies Corp, 2021
Pipeline by Molecular Partners AG, 2021
Pipeline by PlateletBio, 2021
Pipeline by Yichang Humanwell Pharmaceutical Co Ltd, 2021
Pipeline by Yooyoung Pharm Co Ltd, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Dormant Products, 2021 (Contd..2)
Dormant Products, 2021 (Contd..3)
Discontinued Products, 2021
LIST OF FIGURES
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021
